Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Canada Silver Cobalt Works Inc. stock logo
CCW
Canada Silver Cobalt Works
C$0.04
C$0.04
C$0.03
C$0.10
C$12.47M1.67138,291 shs157,067 shs
The GEO Group, Inc. stock logo
GEO
The GEO Group
$14.94
+1.0%
$13.58
$6.94
$16.31
$1.90B0.622.67 million shs540,276 shs
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$0.81
+2.4%
$0.89
$0.67
$3.13
$58.90M0.47689,010 shs365,588 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Canada Silver Cobalt Works Inc. stock logo
CCW
Canada Silver Cobalt Works
0.00%0.00%0.00%0.00%-42.86%
The GEO Group, Inc. stock logo
GEO
The GEO Group
-1.92%+0.14%+1.96%+29.40%+103.16%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-1.42%+0.30%-11.62%-4.76%-66.67%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Canada Silver Cobalt Works Inc. stock logo
CCW
Canada Silver Cobalt Works
N/AN/AN/AN/AN/AN/AN/AN/A
The GEO Group, Inc. stock logo
GEO
The GEO Group
3.4427 of 5 stars
2.53.00.00.03.02.53.1
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
3.5116 of 5 stars
3.21.00.04.60.61.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Canada Silver Cobalt Works Inc. stock logo
CCW
Canada Silver Cobalt Works
N/AN/AN/AN/A
The GEO Group, Inc. stock logo
GEO
The GEO Group
3.00
Buy$18.0020.48% Upside
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
2.33
Hold$11.001,259.70% Upside

Current Analyst Ratings

Latest GEO, DME, CCW, TON, and KZR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/8/2024
The GEO Group, Inc. stock logo
GEO
The GEO Group
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$15.00 ➝ $22.00
3/21/2024
The GEO Group, Inc. stock logo
GEO
The GEO Group
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$15.00
3/15/2024
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
3/13/2024
The GEO Group, Inc. stock logo
GEO
The GEO Group
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$15.00
2/15/2024
The GEO Group, Inc. stock logo
GEO
The GEO Group
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$14.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Canada Silver Cobalt Works Inc. stock logo
CCW
Canada Silver Cobalt Works
C$-176.99K-70.47C$0.00 per share14.17N/A
The GEO Group, Inc. stock logo
GEO
The GEO Group
$2.41B0.79$2.01 per share7.45$10.23 per share1.46
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$7M8.41N/AN/A$2.58 per share0.31

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Canada Silver Cobalt Works Inc. stock logo
CCW
Canada Silver Cobalt Works
-C$7.77M-C$0.06N/AN/AN/A-393.93%-82.21%N/A
The GEO Group, Inc. stock logo
GEO
The GEO Group
$107.32M$0.7619.6610.911.494.72%9.43%3.18%5/7/2024 (Confirmed)
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$101.87M-$1.41N/AN/AN/AN/A-43.08%-37.59%5/9/2024 (Estimated)

Latest GEO, DME, CCW, TON, and KZR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
The GEO Group, Inc. stock logo
GEO
The GEO Group
$0.19N/A-$0.19N/AN/AN/A  
3/14/2024Q4 2023
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$0.39-$0.35+$0.04-$0.26N/AN/A
2/15/202412/31/2023
The GEO Group, Inc. stock logo
GEO
The GEO Group
$0.18$0.29+$0.11$0.37$597.47 million$608.28 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Canada Silver Cobalt Works Inc. stock logo
CCW
Canada Silver Cobalt Works
N/AN/AN/AN/AN/A
The GEO Group, Inc. stock logo
GEO
The GEO Group
N/AN/AN/AN/AN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Canada Silver Cobalt Works Inc. stock logo
CCW
Canada Silver Cobalt Works
1.05
0.37
0.86
The GEO Group, Inc. stock logo
GEO
The GEO Group
1.34
1.21
1.21
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
0.05
11.66
11.66

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Canada Silver Cobalt Works Inc. stock logo
CCW
Canada Silver Cobalt Works
N/A
The GEO Group, Inc. stock logo
GEO
The GEO Group
76.10%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
67.90%

Insider Ownership

CompanyInsider Ownership
Canada Silver Cobalt Works Inc. stock logo
CCW
Canada Silver Cobalt Works
0.78%
The GEO Group, Inc. stock logo
GEO
The GEO Group
5.30%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
7.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Canada Silver Cobalt Works Inc. stock logo
CCW
Canada Silver Cobalt Works
N/A311.80 millionN/ANot Optionable
The GEO Group, Inc. stock logo
GEO
The GEO Group
16,400126.90 million120.17 millionOptionable
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
5872.80 million67.05 millionNot Optionable

GEO, DME, CCW, TON, and KZR Headlines

SourceHeadline
Kezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Up 5.6% in MarchKezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Up 5.6% in March
americanbankingnews.com - April 16 at 1:26 AM
Kezar Life Sciences (NASDAQ:KZR) Trading Down 6.2%Kezar Life Sciences (NASDAQ:KZR) Trading Down 6.2%
marketbeat.com - April 16 at 12:43 AM
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
businesswire.com - April 8 at 4:01 PM
From Pennies to Fortunes: 3 Stocks Set to Make MillionairesFrom Pennies to Fortunes: 3 Stocks Set to Make Millionaires
investorplace.com - March 27 at 4:30 PM
Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026Diamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026
investorplace.com - March 16 at 6:56 AM
KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023
investorplace.com - March 14 at 10:03 PM
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business UpdateKezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
businesswire.com - March 14 at 4:01 PM
Everest Medicines Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for NefeconEverest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon
finanznachrichten.de - March 12 at 3:21 PM
Kezar Life Sciences, Inc. (KZR)Kezar Life Sciences, Inc. (KZR)
finance.yahoo.com - March 3 at 2:56 PM
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care ConferenceKezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
finance.yahoo.com - February 28 at 5:39 PM
Everest Medicines & Kezar Life Sciences receive China NMPA nod to begin phase 2b PALIZADE trial of zetomipzomib in patients with lupus nephritisEverest Medicines & Kezar Life Sciences receive China NMPA nod to begin phase 2b PALIZADE trial of zetomipzomib in patients with lupus nephritis
pharmabiz.com - February 28 at 2:37 AM
Buy Rating Affirmed for Kezar Life Sciences Amidst Progress in Lupus Nephritis Treatment and Expansion into Chinese MarketBuy Rating Affirmed for Kezar Life Sciences Amidst Progress in Lupus Nephritis Treatment and Expansion into Chinese Market
markets.businessinsider.com - February 27 at 4:36 PM
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus NephritisEverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
businesswire.com - February 26 at 6:30 PM
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus NephritisEverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
prnewswire.com - February 26 at 6:10 PM
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
investorplace.com - February 25 at 2:12 PM
Kezar Life Sciences Stock (NASDAQ:KZR) Dividends: History, Yield and DatesKezar Life Sciences Stock (NASDAQ:KZR) Dividends: History, Yield and Dates
benzinga.com - February 22 at 12:59 AM
Kezar Life Sciences Inc.Kezar Life Sciences Inc.
thestreet.com - February 19 at 7:24 PM
3 Penny Stocks Poised for an Unbelievable 1,000% Jump3 Penny Stocks Poised for an Unbelievable 1,000% Jump
finance.yahoo.com - February 10 at 9:24 AM
Kezar Life Sciences Inc KZRKezar Life Sciences Inc KZR
morningstar.com - January 31 at 6:24 PM
KZR Jan 2025 17.500 callKZR Jan 2025 17.500 call
finance.yahoo.com - January 18 at 5:16 PM
Kezar Life Sciences: Results Of Operations And Financial ConditionKezar Life Sciences: Results Of Operations And Financial Condition
cbonds.com - January 10 at 1:58 PM
Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive GrowthBull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth
finance.yahoo.com - December 26 at 8:31 AM
Kezar Life Sciences: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of ListingKezar Life Sciences: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing
cbonds.com - December 6 at 10:38 AM
Everest inches towards clinical studies for renal disease drug in ChinaEverest inches towards clinical studies for renal disease drug in China
msn.com - December 5 at 2:26 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Canada Silver Cobalt Works logo

Canada Silver Cobalt Works

CVE:CCW
Canada Silver Cobalt Works Inc., together with its subsidiaries, engages in the acquisition, evaluation, exploration, and development of mineral properties in Canada. The company primarily explores for silver, cobalt, nickel, gold, and copper, as well as platinum and palladium deposits. The company was formerly known as Canada Cobalt Works Inc. and changed its name to Canada Silver Cobalt Works Inc. in May 2020. Canada Silver Cobalt Works Inc. is headquartered in Coquitlam, Canada.
The GEO Group logo

The GEO Group

NYSE:GEO
The GEO Group, Inc. (NYSE: GEO) engages in ownership, leasing, and management of secure facilities, processing centers, and community-based reentry facilities in the United States, Australia, the United Kingdom, and South Africa. The company also provides secure facility management services, including the provision of security, administrative, rehabilitation, education, and food services; reentry services, such as temporary housing, programming, employment assistance, and other services; electronic monitoring and supervision services; and transportation services; as well as designs, constructs, and finances new facilities through projects. The company was founded in 1984 and is based in Boca Raton, Florida.
Kezar Life Sciences logo

Kezar Life Sciences

NASDAQ:KZR
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.